New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

The epicentre was around 80 km north of Mount Everest, the world's highest mountain and a popular destination for climbers and trekkers. Asia Pacificcategory Tremors in earthquake-prone Tibet 12: ...